Pacira (PCRX) BioSciences announced an upcoming podium presentation of findings from its Phase 1 study of PCRX-201, a locally administered gene therapy candidate for osteoarthritis of the knee. The data will be presented at the 28th Annual Meeting of the American Society of Gene and Cell Therapy in New Orleans on May 15. The presentation will highlight how preexisting and treatment-induced neutralizing antibodies impact the therapy’s efficacy, safety, and redosing potential.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCRX: